How MS Care Has Evolved Since the COVID-19 Pandemic - Final Assessment
The following questions are intended to assess your gained knowledge and practice of key aspects in the management of patients with MS and COVID.
Alexander Gill, MD
Neuroimmunology and Neuroinfectious Disease Clinical
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Alexander J. Gill is a neurologist in Baltimore, Maryland and is affiliated with Johns Hopkins Hospital. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice between 6-10 years.1.
Describe considerations for DMT initiation and continuation in patients depending on SARS-CoV-2 infection risk, COVID-19 severity risk, and vaccination status.
2.
Review individual and class characteristics of DMTs, specifically with focus on effects on implications on COVID-19 severity and effects on vaccination immune responses
3.
Apply this knowledge to help with DMT selection, continuation, holding, discontinuation, or switching in MS patients as a result of COVID infection or infection risk.
